Coave Signs an Exclusive License Agreement with Théa to Co-Development and Commercialize CTx-PDE6b for PDE6b Associated Retinitis Pigmentosa in EU

 Coave Signs an Exclusive License Agreement with Théa to Co-Development and Commercialize CTx-PDE6b for PDE6b Associated Retinitis Pigmentosa in EU

Coave Signs an Exclusive License Agreement with Théa to Co-Development and Commercialize CTx-PDE6b for PDE6b Associated Retinitis Pigmentosa in EU

Shots:

  • Coave to receive $11.7M up front & equity investment, ~ $76.5M as clinical development, regulatory & commercial milestones along with royalties on net sales of the product. Both companies will co-develop Coave’s CTx-PDE6b & share the development costs
  • Théa obtains an exclusive license to commercialize the therapy in the EU, Ukraine, Turkey, Russia, and North Africa. Coave retains the rights to commercialize CTx-PDE6b in the US
  • CTx-PDE6b is a novel AAV-based gene therapy that is designed to deliver a non-mutated copy of the PDE6b gene into the subretinal space. The therapy is currently being evaluated in the P-I/II trial to determine its safety & efficacy

Click here to­ read full press release/ article | Ref: PR Newswire | Image: Coave Therapeutics

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post